Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ProQR Therapeutics (PRQR) Invested Capital (2016 - 2025)

ProQR Therapeutics' Invested Capital history spans 6 years, with the latest figure at $70.4 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 34.91% to $70.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $70.4 million, a 34.91% decrease, with the full-year FY2025 number at $70.4 million, down 34.91% from a year prior.
  • Invested Capital hit $70.4 million in Q4 2025 for ProQR Therapeutics, down from $108.1 million in the prior quarter.
  • Over the last five years, Invested Capital for PRQR hit a ceiling of $175.8 million in Q4 2021 and a floor of $79903.5 in Q1 2021.
  • Historically, Invested Capital has averaged $98.2 million across 5 years, with a median of $77.0 million in 2022.
  • The widest YoY moves for Invested Capital: up 195418.42% in 2022, down 59.22% in 2022.
  • Tracing PRQR's Invested Capital over 5 years: stood at $175.8 million in 2021, then crashed by 52.47% to $83.5 million in 2022, then dropped by 26.8% to $61.1 million in 2023, then surged by 76.84% to $108.1 million in 2024, then crashed by 34.91% to $70.4 million in 2025.
  • Business Quant data shows Invested Capital for PRQR at $70.4 million in Q4 2025, $108.1 million in Q4 2024, and $61.1 million in Q4 2023.